Activities
Cosmo has a deep and broad expertise in the development of
gastro-intestinal (GI) pharmaceutical products with a specific
focus on Inflammatory Bowel Disease, based on the company’s
innovative and proprietary MMX® technology. The
company has built a successful and profitable pharmaceutical
manufacturing business manufacturing products for international
companies and in 2006 trebled its manufacturing capacity by adding
a state-of-the-art, FDA-approved plant (for the production of
Lialda®/Mezavant®), intended for the
manufacturing of its own products.
The company’s proprietary MMX® technology
is at the core of the product pipeline and was developed from its
expertise in formulating and manufacturing GI pharmaceutical
products for international clients. The research led to new patents
that increased the efficacy of existing pharmaceutical products by
modifying their formulations and tailoring their optimized delivery
systems.
The company is engaged in the following activities:
Product Pipeline
Development, licensing and commercialisation of proprietary
pharmaceutical products, primarily focused on the treatment of
Inflammatory Bowel Diseases, colon infections and other colon
diseases.
Read more
Manufacturing
Manufacturing of pharmaceutical products for third parties and the
provision of related services.
Read more
Technology
MMX® Multi Matrix Technology
Read more